Cannabis Reclassification: What the Upcoming DEA Hearing Mean for Consumers
The Biden administration started a push to change how the federal government treats cannabis. The Department of Justice now recommends moving cannabis from Schedule I to Schedule III. That’s a major shift.
The DEA hearing on this change was set for January 21, 2025. It has since been postponed after an appeal. Still, this hearing could reshape the entire cannabis industry how it’s regulated, who can access it, and how the public sees it.
Below, we break down what this could mean for you, whether you’re a consumer, a patient, or a business owner.
A Hearing Timed Near MLK Day
The hearing was scheduled just one day after Martin Luther King Jr. Day. That timing isn’t lost on advocates.
Cannabis laws have hit some communities harder than others. Reclassification could help fix that. Possible outcomes include:
- Fewer arrests tied to nonviolent cannabis offenses
- Expungement of past convictions for some offenders
- More equitable access to the legal cannabis market
Supporters call this a step toward restorative justice using drug policy reform to address old harms.
Schedule I vs. Schedule III: The Basics
Here’s the simple version of a complex topic.
Schedule I currently includes cannabis, alongside heroin and LSD. This label means the government sees these substances as:
- High risk for abuse
- Having no accepted medical use
Schedule III includes drugs like ketamine and anabolic steroids. These substances are seen as:
- Having real medical benefits
- Carrying a lower risk of abuse
Moving cannabis to Schedule III would officially recognize its medical value. It would also ease some of the legal walls blocking cannabis research.
What This Could Mean for Consumers
1. Easier Access
Schedule III status would loosen federal rules on distribution. That could mean:
- Wider availability for medical and recreational users
- Easier access through doctors and pharmacies for patients
2. Lower Prices
Right now, cannabis businesses face steep taxes under IRS code Section 280E. Reclassification could:
- Cut that tax burden
- Lower prices at the register
- Make legal cannabis more competitive with the black market
3. More Research
Schedule I status makes cannabis research slow and bureaucratic. Schedule III would:
- Speed up research approvals
- Let scientists study benefits and risks more freely
- Open the door to new, cannabis-based treatments
4. Less Stigma
Official recognition of medical benefits could shift public opinion. That may lead to:
- More open conversations about cannabis use
- Less judgment toward everyday consumers
5. Rules Still Vary by State
Federal reclassification wouldn’t replace state law. Cannabis users still need to:
- Know their state’s specific rules
- Track how state law interacts with the new federal status
Why the DEA Has the Final Say
The DEA leads this process. It reviews input from health agencies, including the Department of Health and Human Services (HHS). From there, the DEA decides if cannabis’s medical value justifies a new schedule.
Federal support for reclassification has been growing. But the DEA’s final ruling will set the real boundaries of any change.
The Case For and Against Reclassification
Why Supporters Want It
- Medical relief: Cannabis helps with chronic pain, epilepsy, and multiple sclerosis.
- Economic upside: More tax revenue, new jobs, and lower enforcement costs.
- Fairness: A path toward expungement and equity for those harmed by past enforcement.
Why Critics Push Back
- Abuse risk: Concern remains about misuse, especially among young people.
- Big Pharma worries: Critics fear large companies could dominate the market and crowd out natural products.
- Messy rollout: Updating laws and systems could create confusion in the short term.
What to Watch For
- DEA updates — official statements will clarify the timeline.
- State reactions — states may adjust their own rules in response.
- New legislation — Congress could step in on tax and banking issues.
- Industry changes — expect new products and pricing as businesses adjust.
The Bigger Picture
A federal reclassification wouldn’t just affect cannabis users. It could ripple across the economy and society.
Economic growth: New jobs and tax revenue as the industry expands.
Restorative justice: Relief for communities hit hardest by past cannabis laws, through reduced penalties and record expungements.
Global influence: A U.S. policy shift could push other countries to rethink their own cannabis laws.
Bottom Line
Cannabis reclassification could be a turning point for consumers, for businesses, and for society. Easier access, less stigma, and more research are all on the table.
As the Trump administration takes office, it’s still unclear how this will play out. We’ll keep watching and reporting as the story develops.
At VFI, we help cannabis businesses navigate a fast-changing industry. Get in touch to learn how we can support your growth.